- Home
- AXSM vs CLVT Comparison
AXSM vs CLVT Comparison
Compare AXSM & CLVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AXSM
- CLVT
- Stock Information
- Founded
- AXSM 2012
- CLVT 2016
- Country
- AXSM United States
- CLVT United Kingdom
- Employees
- AXSM N/A
- CLVT N/A
- Industry
- AXSM Biotechnology: Pharmaceutical Preparations
- CLVT EDP Services
- Sector
- AXSM Health Care
- CLVT Technology
- Exchange
- AXSM Nasdaq
- CLVT Nasdaq
- Market Cap
- AXSM 4.0B
- CLVT 3.7B
- IPO Year
- AXSM 2015
- CLVT N/A
- Fundamental
- Price
- AXSM $93.19
- CLVT $6.68
- Analyst Decision
- AXSM Strong Buy
- CLVT Hold
- Analyst Count
- AXSM 14
- CLVT 7
- Target Price
- AXSM $125.67
- CLVT $7.64
- AVG Volume (30 Days)
- AXSM 391.1K
- CLVT 4.7M
- Earning Date
- AXSM 11-04-2024
- CLVT 08-06-2024
- Dividend Yield
- AXSM N/A
- CLVT N/A
- EPS Growth
- AXSM N/A
- CLVT N/A
- EPS
- AXSM N/A
- CLVT N/A
- Revenue
- AXSM $291,489,000.00
- CLVT $2,602,400,000.00
- Revenue This Year
- AXSM $42.85
- CLVT $1.00
- Revenue Next Year
- AXSM $69.55
- CLVT $2.03
- P/E Ratio
- AXSM N/A
- CLVT N/A
- Revenue Growth
- AXSM 59.73
- CLVT N/A
- 52 Week Low
- AXSM $55.02
- CLVT $4.97
- 52 Week High
- AXSM $98.40
- CLVT $9.61
- Technical
- Relative Strength Index (RSI)
- AXSM 64.50
- CLVT 56.32
- Support Level
- AXSM $88.04
- CLVT $6.57
- Resistance Level
- AXSM $97.00
- CLVT $6.89
- Average True Range (ATR)
- AXSM 3.03
- CLVT 0.21
- MACD
- AXSM 0.49
- CLVT 0.01
- Stochastic Oscillator
- AXSM 64.58
- CLVT 58.65
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
About CLVT Clarivate Plc
Clarivate is a data, information, and software workflow solutions company serving customers primarily in academia, government, law, life sciences, and healthcare. The company was formerly part of Thomson Reuters before being sold to private equity as an independent company in 2016. In 2019, Clarivate went public on the New York Stock Exchange. Around half of the company's revenue is generated in the Americas while Europe, Middle East, and Africa account for around a quarter.